Browsing: Bispecifics

At the 2026 Society of Hematologic Oncology (SOHO) Annual Meeting, Noopur Raje, MD, director of the Center for Multiple Myeloma…

As CAR T-cell therapy and bispecific antibodies expand in multiple myeloma, CELMoDs such as iberdomide (Zenbexus) are being explored as…

In a CancerNetwork® Face-Off event, experts in the multiple myeloma field divided into 2 teams to discuss the efficacy, safety,…

Marco Davila, MD, PhD, posed a question to Joshua Richter, MD: with bispecific antibodies available off the shelf and without…

Bispecific antibodies and CAR T-cell therapy are both recommended treatment options for patients with relapsed/refractory follicular lymphoma after the second…

You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual…

Following the 2026 National ICE-T Conference in Charlotte, North Carolina, Prerna Mewawalla, MD, spoke with CancerNetwork® about important considerations for…

In a conversation with CancerNetwork®, Barry Paul, MD, discussed highlights and key ideas from the 2026 National Immune Cell Effector…

In this segment on early relapse multiple myeloma, Luciano Costa raises a critical and ongoing debate regarding optimal sequencing of…

Ralph V. Boccia, MD, FACP, highlighted that the launch of The Bispecifics Network across CancerNetwork, The American Journal of Managed…